ABC: Multiplexing the Future of eCLIP

Eclipsebio is excited to announce the publication of “Multiplexed transcriptome discovery of RNA binding protein binding sites by antibody-barcode eCLIPin Nature Methods. This manuscript details a new breakthrough method invented by our Eclipsebio R&D team lead by scientist Daniel Lorenz, with contributions from the Yeo lab at UCSD. The new method utilizes barcoded antibodies to assess multiple RBPs per individual sample, drastically increasing our ability to annotate RBP-RNA interactions.

Eclipsebio was founded in 2017 with the mission to make cutting edge RNA technologies more accessible. One of Eclipsebio’s core technologies is RBP-eCLIP (enhanced cross-linking and immunoprecipitation). This landmark method, established by UCSD professor and Eclipsebio co-founder Gene Yeo, was designed to be a dependable and robust technology for studying RBP-RNA interactions With a validated antibody for an RBP of interest, scientists could now map RBP binding sites on RNAs transcriptome-wide. Estimates have predicted over 1500 RBPs in the human genome, and many of these RBPs have already been shown to play a critical role in modulating RNA stability and function. 

While RBP-eCLIP is an incredibly powerful tool, it presents some difficulty when one is looking for upward scalability. Each RBP must be assessed individually with a multi-day protocol, making assessments of multiple RBPs such as reader/writers or splicing factors extremely demanding in time, labor, and plastic consumables.  

At Eclipsebio, we are always looking to enable faster scientific breakthroughs and new therapeutic discoveries to help improve the lives of those around us more quickly. In the name of constant innovation, the R&D team has developed antibody-barcode eCLIP (AB-CLIP for short). Like RBP-eCLIP, AB-CLIP enables the discovery of RBP-RNA interactions with distinct and significant advantages. Namely, we can now annotate the RBP-RNA interactions for multiple RBPs per individual sample.  

AB-CLIP accurately detects the binding features for at least 10 different RBPs from a single experimental sample, vastly reducing sample input amounts when scaled. This new technology will help facilitate more RBP binding maps in disease-relevant cell types, furthering our mission of making the detection or RBP-RNA interactions even more accessible. Stay tuned for more updates and reach
out to us at with any questions or comments.